Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-directed medical therapy for heart failure with reduced ejection fraction. Recent trials clearly established the efficacy of SGLT2 inhibitors on cardiac remodeling while preventing renal function decline in patient...
Main Authors: | Ting-Wei Kao, Chin-Chou Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1086672/full |
Similar Items
-
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017-05-01) -
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
by: Věra Čertíková Chábová, et al.
Published: (2022-03-01) -
Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
by: Ting-Yung Chang, et al.
Published: (2022-04-01) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01) -
Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
by: Yi‐Fang Weng, et al.
Published: (2023-04-01)